Making Medicine

Incubate Coalition

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

  1. 1d ago

    China’s Biotech Rise: What Tim Scott Saw Inside Shanghai

    China's biotech innovation is accelerating. Clinical trials, NIH funding, and global competition are reshaping healthcare. Biocom’s President & CEO Tim Scott explains why America should focus on "playing to win" rather than "playing not to lose." China’s biotech industry is moving faster than many policymakers realize. From investigator-initiated clinical trials and massive patient registries to government-backed investment strategies, China is rapidly becoming a major force in global drug development. This week on the Making Medicine Podcast, John Stanford sits down with Tim, fresh off a biotech delegation trip to Shanghai. He shares firsthand observations from China's rapidly growing life sciences ecosystem, what surprised him most, and what American biotech leaders should learn from the experience. This Episode Covers 🔹 Why major pharmaceutical companies are increasingly sourcing innovation from China 🔹 How China’s investigator-initiated trial system accelerates drug development 🔹 The role of patient registries and trial-ready cohorts 🔹 Why China is becoming a global biotech powerhouse 🔹 The debate over biosecurity, protectionism, and global scientific collaboration 🔹 NIH funding, workforce development, and America’s innovation advantage 🔹 How the United States can remain the world leader in biotechnology One of the most thought-provoking moments comes when Tim compares the biotech race to the New York Knicks' championship run, arguing that America must focus on "playing to win" through investment, innovation, NIH funding, and scientific leadership rather than simply "playing not to lose" by slowing competitors down. The analogy becomes a powerful framework for understanding the choices facing US policymakers as China continues to expand its role in global drug development. The conversation ultimately challenges listeners to think beyond today's headlines and consider how the United States can maintain its leadership in biotechnology while continuing to deliver breakthrough medicines for patients around the world. The question is no longer whether China matters in biotech. The question is how America responds. Will the US continue playing to win through investment and innovation, or will it focus primarily on slowing competitors down? Watch the full episode and Join the Conversation ⬇️ Do you believe China is now a permanent biotech superpower? Can the United States maintain its leadership in biomedical innovation? Should scientific collaboration continue despite growing geopolitical tensions? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more biotech and healthcare policy coverage. Timestamps 00:00 China Biotech Competition 01:00 California Life Sciences Leadership 07:45 Pharma Licensing Deals in China 13:10 China Clinical Trials Explained 20:00 Drug Pricing and Biotech Innovation 23:18 Shanghai Biotech Ecosystem 25:28 China's Biotechnology Growth Strategy 35:28 Biosecurity and US-China Biotech Policy 40:20 Playing to Win in Biotech 42:10 Knicks Analogy and Innovation Leadership 43:20 NIH Funding and American Innovation 47:35 AI, China and the Future of Biotechnology 49:58 Outro  DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #Biotech #China #DrugDevelopment #ClinicalTrials #HealthcarePolicy

    51 min

  2. Jun 11

    Patient Advocacy, FDA Partnerships & Building the Infrastructure of Drug Discovery

    Rare diseases. Patient advocacy. Drug development. FDA partnerships. Clinical trials. Patient organizations have evolved into powerful engines of drug development, building registries, funding research, shaping clinical trial design, and partnering with regulators to accelerate new treatments. This week on the Making Medicine Podcast, John Stanford sits down with Lisa Bonebrake, Executive Director of the Alport Syndrome Foundation, and Janis Naeve, world-class VC and Co-Founder & Partner of Bright Frontier, to discuss the evolving, high-impact role of patient organizations in modern drug development. Patient advocacy groups are building the critical data and clinical infrastructure required to advance medical research. Lisa shares how the Alport Syndrome Foundation is directly de-risking clinical trials, building global patient registries, and driving the ASCENT Initiative, a historic public-private partnership with the FDA to establish surrogate endpoints for kidney disease. The discussion also explores the venture capital perspective with Janis Naeve, highlighting why investors view patient-led data infrastructure as a "highway" for innovation, how pharmaceutical companies can successfully integrate patient feedback into trial design, and why establishing clear regulatory pathways is vital to accelerating rare disease treatments. This Episode Covers 🔹 Why patient advocacy groups are the new infrastructure of drug discovery 🔹 The real impact of Alport syndrome and the importance of early genetic testing 🔹 The ASCENT Initiative and establishing surrogate endpoints with the FDA 🔹 The impact of Alport syndrome and the importance of early genetic testing 🔹 Why pharmaceutical companies must include patient voices in clinical trial design  🔹 The venture capital perspective on funding rare disease innovation 🔹 Regulatory clarity and de-risking biotech investment 🔹 How public-private partnerships accelerate the timeline for lifesaving treatments Patient advocates are no longer passive charities, they are the essential infrastructure of modern drug discovery. This conversation serves as a blueprint for the future of healthcare policy, exploring how rare disease organizations are partnering with the FDA, saving pharma millions by rescuing flawed clinical trials, and driving venture capital investment to accelerate lifesaving treatments. Join the Conversation ⬇️ Should patient organizations have a larger role in shaping FDA regulatory pathways? What's the biggest obstacle preventing more rare disease drug development? How can policymakers better support patient-led research infrastructure? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more biotech and healthcare policy coverage. Timestamps 0:00 - The Real ROI of Patient Advocacy 0:26 - Welcome to the Making Medicine Podcast 1:52 - Breaking News in Alport Syndrome Research 4:03 - What is Alport Syndrome? 5:58 - Redefining the Role of Patient Organizations 9:09 - A VC Investor’s Perspective on Rare Disease 11:38 - The ASCENT Initiative & FDA Public-Private Partnership 18:03 - Understanding Surrogate Endpoints in Clinical Trials 25:19 - How to Build a Fearless Patient Advocacy Group 30:26 - Why Pharma Needs to Listen Directly to Patients 35:31 - Educating the Biotech Industry on Patient Integration 39:35 - Key Takeaways for Policymakers and Investors DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #rarediseases #drugdevelopment #clinicaltrials #fda #biotech #patientadvocacy #makingmedicine #podcast

    42 min

  3. Jun 4

    Healthcare Costs, PBMs & Why Manufacturers Oppose Drug Price Controls

    Healthcare costs. PBM reform. Drug price controls. FDA stability. American manufacturing. This week on the Making Medicine Podcast, John Stanford sits down with Charles Crain, Vice President of Domestic Policy at the National Association of Manufacturers, to discuss a new report examining the rising cost of healthcare and its impact on American manufacturers. Manufacturers provide health coverage to millions of workers, making healthcare affordability a major business concern. But according to NAM, the solution isn't limiting pharmaceutical innovation. Instead, the conversation focuses on PBM reform, 340B program transparency, regulatory certainty, preventative care, and policies that lower costs without undermining America's leadership in medical innovation. The discussion also explores why FDA stability matters beyond the biotech sector, how regulatory uncertainty affects long-term investment, and what policymakers should prioritize to strengthen American competitiveness in the face of growing global competition.  This Episode Covers: 🔹 Why healthcare costs are manufacturers' top business concern 🔹Why NAM opposes pharmaceutical price controls 🔹The real drivers of rising healthcare costs 🔹PBM reform and prescription drug transparency 🔹The 340B program and hospital incentives 🔹Why FDA stability matters for innovation 🔹Regulatory certainty and biotech investment 🔹Manufacturing, R&D, and American competitiveness 🔹Lessons from COVID supply chain vulnerabilities 🔹How to compete with China through innovation At the center of this conversation is a simple question: How do we lower healthcare costs without weakening the innovation ecosystem that develops new medicines? Charles Crain argues that affordability and innovation are not competing goals, and that policymakers should focus on the structural drivers of healthcare spending rather than policies that could reduce future medical breakthroughs. Check out the NAM report: "Prescription for a Healthy Workforce: Manufacturers' Roadmap to Lower Healthcare Costs" https://nam.org/issues/health-care/  Join the Conversation ⬇️ Are policymakers focusing on the right drivers of healthcare costs? Should PBM reform be a higher priority than drug price controls? What matters most for U.S. competitiveness: tax policy, regulatory certainty, or innovation incentives? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod  Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology. Timestamps 00:00 Intro & Disclaimer 00:37 Meet Charles Crain & NAM 01:03 Why Manufacturers Care About Healthcare Costs 03:24 Why Healthcare Costs Keep Rising 05:57 What NAM Would Do to Lower Costs 08:03 Why Manufacturers Oppose Drug Price Controls 09:20 The Innovation Tradeoff Explained 10:54 Understanding the 340B Program 13:16 PBMs & Healthcare Middlemen 15:09 How Powerful Are PBMs? 17:13 Why FDA Stability Matters 18:16 Regulatory Costs & Uncertainty 19:30 Why Biotech Needs Predictable Rules 20:43 Building Bipartisan Policy Solutions 23:18 Competing With China Through Innovation 25:12 Final Thoughts DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #healthcarepolicy #pbm #biotech #drugpricing #fda #manufacturing #makingmedicine

    27 min

  4. May 28

    Rep. Scott Peters on the Pill Penalty, PBMs, China & America’s Biotech Future

    China and biotech competition. Drug pricing reform. The FDA. PBMs. America’s innovation economy. This week on the Making Medicine Podcast, John Stanford sits down with Rep. Scott Peters to discuss the future of American biotech innovation, the importance of ending the “pill penalty,” and why China’s rapid rise in biotechnology is becoming a major strategic concern for the United States. Representing one of the country’s leading biotech hubs in San Diego, Congressman Peters explains why policies tied to the Inflation Reduction Act and investment incentives directly impact whether innovative medicines get funded, developed, and brought to patients. The conversation also explores the future of PBM reform, rare disease investment, FDA modernization, the workforce and scientific talent, supply chain security, and what policymakers must do to keep America competitive in biotech and life sciences innovation. This episode covers: 🔹 Why San Diego became a biotech powerhouse 🔹 The “pill penalty” and the EPIC Act 🔹 How the IRA changed biotech investment incentives 🔹 Why rare disease investment rebounded after the ORPHAN Cures Act 🔹 China’s growing role in global biotech innovation 🔹 FDA modernization and regulatory competitiveness 🔹 Immigration, talent, and scientific leadership 🔹 PBM reform and healthcare affordability 🔹 Why diagnostics and genomics may transform healthcare 🔹 The importance of bipartisan problem-solving in healthcare policy At the center of the discussion is one core issue: competitiveness. Congressman Peters argues that America’s advantage in biotech depends on stable investment incentives, strong scientific institutions, private-sector innovation, and policies that continue attracting talent and capital into the United States. Check out more from Incubate Coalition: https://www.incubatecoalition.org/ Join the Conversation ⬇️ Do you think the United States is doing enough to stay competitive with China in biotech innovation? Should Congress further reform the IRA to encourage more biotech investment and drug development? What matters most for the future of American healthcare innovation: FDA modernization, PBM reform, or stronger investment incentives? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology. Timestamps 00:00 Intro & Disclaimer 00:17 Why China Is Catching Up in Biotech 00:31 Meet Congressman Scott Peters 01:28 Why San Diego Became a Biotech Hub 03:24 The Role of NIH & Research Institutions 05:02 Venture Capital & Biotech Growth 07:06 The “Pill Penalty” Explained  08:05 The IRA & Medicare Drug Negotiation 09:25 Why Investment Incentives Matter 11:11 How Small Molecule Investment Was Affected 12:20 Political Risks of Supporting Biotech 15:17 Why Independence Still Matters in Congress 21:26 Rare Disease Investment & Orphan Cures Act 24:00 China’s Rise in Biotech Innovation 25:27 FDA Challenges & Global Competition 27:19 Immigration, Talent & Scientific Leadership 30:25 PBM Reform & Healthcare Costs 33:19 Diagnostics, Genomics & Preventive Medicine 34:19 Why Congress Needs Better Biotech Education 36:35 Closing Thoughts DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #fda #biotech #drugpricing #china #pbm #healthcarepolicy #innovation

    37 min

  5. May 21

    The FDA Decoded: Roles, Responsibilities & What They Mean for Drug Development

    What does the FDA actually look like on the inside — and why does its structure matter for drug approvals, rare disease therapies, and biotech investment? This week on the Making Medicine Podcast, host John Stanford is joined by Jef Akst, senior editor at BioSpace, to break down the FDA's key divisions, what each one is responsible for, and how they shape the drug development landscape. Jef walks through the roles of CDER (Center for Drug Evaluation and Research) and CBER (Center for Biologics Evaluation and Research) — what each center oversees, how they differ, and why their review processes matter to biotech companies navigating approval timelines. The episode also explains how FDA advisory committees work, what authority they hold, and how their recommendations influence regulatory outcomes. The conversation then expands to the broader policy environment shaping biotech today — including CMS marketplace rule changes that affect patient cost exposure, Section 232 pharmaceutical tariff procedures, Most Favored Nation pricing, and the Orphan Cures Act. The episode closes with data from the INCUBATE Coalition's biotech investment tracker, examining how IRA policy and regulatory uncertainty are influencing capital allocation across the life sciences sector. Check out the full report from Manatt Health https://www.incubatecoalition.org/post/one-pager-complete-report-regulatory-instability-at-fda-is-reshaping-biotech-investment Check out INCUBATE'S biotech investment tracker https://lifesciencetracker.com/ Join the Conversation ⬇️ Do you think FDA leadership turnover is creating too much uncertainty for biotech companies and investors? Should the FDA rely more heavily on advisory committees and outside scientific experts during periods of instability? How should policymakers balance lower healthcare premiums with the risk of higher out-of-pocket costs for patients? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:  X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like, follow, and subscribe for more conversations on FDA policy, biotech innovation, healthcare regulation, drug pricing, rare disease development, and life sciences investment. Time Stamps 00:00 Intro & Disclaimer 00:17 FDA Instability & Biotech Uncertainty 00:39 Meet BioSpace’s Jef Akst 01:51 FDA, HHS & RFK Jr. Influence 04:13 What CDER Does 05:55 Drug Delays & FDA Inconsistency 07:23 What CBER Does 10:33 Office of Therapeutic Products Turnover 13:08 FDA Commissioner’s Role Explained 15:17 Advisory Committees & Expert Panels 18:00 CMS ACA Rule Changes 19:24 Pharma Tariffs & MFN Pricing 21:06 Senator Bill Cassidy’s Primary Loss 22:50 New Biotech Investment Tracker Data 24:41 Rare Disease Investment Trends 25:17 Closing Thoughts DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #FDA #Biotech #HealthcarePolicy #DrugDevelopment #RareDisease #CMS #Pharma #LifeSciences #MFN #MakingMedicine

    26 min

  6. May 14

    FDA Leadership After Marty Makary: What Biotech Needs Next

    FDA instability. AI in clinical trials. China overtaking the United States in biotech development. Following news that Marty Makary has stepped down as FDA commissioner, questions around regulatory stability, scientific leadership, and the future of biotech innovation are back in focus. This week on the Making Medicine Podcast, John Stanford examines what the FDA needs most during periods of leadership transition: scientific credibility, regulatory expertise, and a stable, predictable process for developing new medicines. Recorded before the latest leadership announcement, this episode focuses less on personalities and more on the broader institutional questions shaping the future of drug development, clinical trials, AI-enabled regulation, rare disease research, and America’s global competitiveness in biotech. This episode covers:   This episode covers: 🔹 What Marty Makary’s departure could mean for the FDA 🔹 Why FDA stability matters for biotech investment 🔹 The qualities that define effective FDA leadership 🔹 AI, clinical trials, and the future of drug development 🔹 FDA modernization and new approach methodologies 🔹 Rare disease development and regulatory predictability 🔹 Why global biotech competition is accelerating 🔹 How FDA credibility impacts patients, investors, and innovation At the center of the conversation is one core issue: confidence. Confidence that the FDA remains a science-driven institution capable of supporting innovation while ensuring drugs are safe and effective for American patients. Because uncertainty at the agency doesn’t just affect markets — it affects clinical timelines, capital allocation, and ultimately whether treatments reach patients. Join the Conversation ⬇️ Do you think the FDA is becoming less predictable? Should AI play a larger role in clinical trials? Can America maintain its leadership in biotech innovation? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true https://www.tiktok.com/@makingmedicinepodcast?lang=en 👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology. Timestamps 00:00 Intro & Disclaimer 00:33 Why FDA Leadership Matters 01:00 FDA Leadership Shakeup Explained 01:50 Why FDA Stability Impacts Biotech 02:14 The Cost Of Regulatory Uncertainty 02:59 The Three Qualities Of A Strong FDA Commissioner 03:51 Why Regulatory Experience Matters 04:40 AI & The Future Of Clinical Trials 05:47 America’s Healthcare Data Problem 06:17 Why The FDA Must Lead On AI 06:41 The Limits Of FDA Authority 07:07 Why Investors Need Predictability 07:33 FDA Modernization & Innovation 07:55 Why This Matters For Patients 08:21 Rare Disease Patients & FDA Stability 08:41 Passage Bio’s FDA Setback 09:27 China Surpasses The U.S. In Drug Trials 10:09 What The Industry Wants From The FDA 10:32 Why Stable Regulation Matters DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #FDA #Biotech #AI #ClinicalTrials #HealthcarePolicy #RareDisease #GeneTherapy #DrugDevelopment #China #MakingMedicine

    11 min

  7. May 7

    FDA Approvals Corner, Immigration Warnings & Germany's MFN Complication | Making Medicine Headlines

    Gene therapy breakthroughs. The first oral GLP-1 pill. A troubling signal for scientific talent. And a German pricing move that could quietly reshape global drug development. This week on the Making Medicine podcast, John Stanford breaks down four stories shaping the future of life sciences and biotech investment. From the FDA's landmark approval of Regeneron's gene therapy for genetic hearing loss to new survey data showing immigration policy is already influencing where top researchers choose to build their careers — the pressure on the innovation ecosystem is building from multiple directions at once. This episode covers: 🔹 FDA Approvals Corner: Eli Lilly's Foundayo (first oral small-molecule GLP-1 for weight management), Regeneron's Otarmeni (gene therapy for genetic hearing loss), and Merck's Idvynso (once-daily HIV treatment). 🔹 Immigration policy and what a new STAT News survey says about the research pipeline. 🔹 Germany's drug discount proposal and why it complicates the U.S. Most Favored Nation pricing strategy. At the center of all these conversations is one critical question: can the United States maintain the confidence, in its regulators, its talent pipeline, and its pricing environment, that keeps the biomedical innovation engine running? Check out the full STAT News Report https://www.statnews.com/2026/05/04/trump-immigration-policy-stat-survey-measures-science-impact/ Join the Conversation ⬇️ Do you think the FDA is becoming less predictable? Should the US rethink its MFN drug pricing strategy? Can America maintain its leadership in biotech innovation? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more conversations on FDA policy, biotech investment, drug pricing, healthcare innovation, China competition, and national security. Time Stamps 00:00 Intro & Disclaimer 00:17 Innovation Ecosystem Runs on Confidence 00:33 FDA, Germany & Biotech Headlines Preview 01:18 FDA Drug Approvals Roundup 01:41 Eli Lilly’s Oral GLP-1 Approval 02:16 Regeneron Gene Therapy Breakthrough 03:18 Immigration Policy & Scientific Talent Concerns 04:56 Germany Challenges MFN Drug Pricing 05:57 Why Global Drug Pricing Could Reshape Launch Strategy 06:49 Rare Disease Investment Risks 07:12 Germany vs Trump MFN Policy 08:08 Why Biotech Innovation Depends on Confidence DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #fda #biotech #drugpricing #glp1 #healthcarepolicy #mfn #germany #regeneron #EliLilly #MakingMedicine

    9 min

  8. Apr 30

    Senator Todd Young on China, FDA Reform, and Why Biotech Is National Security

    Biotech is no longer just about medicine. It is now a frontline issue in national security, global competition, and economic independence. In this episode of the Making Medicine Podcast, Senator Todd Young joins us to break down the growing risks of relying on China for critical biotech inputs, why FDA speed and regulatory clarity matter more than ever, and how the US can stay competitive in a rapidly shifting global landscape. From supply chain vulnerabilities to AI-driven drug development, this conversation explores the intersection of policy, innovation, and national defense. Senator Young also shares insights on drug pricing, biotech investment, and why strengthening the full ecosystem from startups to large manufacturers is critical for long-term US leadership. If the US fails to act, the consequences go far beyond healthcare. They shape who leads the next century of innovation. At stake is not just faster cures, but whether America remains the global leader in biotech or falls behind. Join the Conversation ⬇️ Should the US decouple biotech supply chains from China? Can the FDA move faster without sacrificing safety? What policy change would most strengthen US biotech leadership? Drop your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Time Stamps 00:00 Intro and disclaimer 00:17 Senator Young on China dependency risk 00:33 Meet Senator Todd Young 01:53 Why biotech is national security 03:23 Biotech’s role in defense, materials, and Department of War 04:17 Supply chain resiliency and China risk 05:16 Biotech threats, food security, and countermeasures 06:41 China, biotech standards, and global competition 08:04 Why innovators go abroad for speed and cost 08:46 FDA optimization, AI, and faster drug development 12:16 Indiana’s biotech ecosystem and Eli Lilly 16:32 Why small biotech and big pharma need each other DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #biotech #FDA #China #nationalsecurity #pharma #healthpolicy #innovation #senatortoddyoung

    26 min
See All (82)

Trailer

Ratings & Reviews

5
out of 5
15 Ratings

About

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

Information

  • Creator
    Incubate Coalition
  • Years Active
    2021 - 2026
  • Episodes
    82
  • Rating
    Clean
  • Copyright
    © Copyright Making Medicine Duality
  • Show Website
    Making Medicine

You Might Also Like